While the primary goal of MEK inhibitors is indeed to directly suppress cancer cell growth by blocking aberrant MAPK signaling, emerging research has unveiled an intriguing secondary benefit: the induction of immunological effects within the tumor microenvironment. This evidence concerns the gene MAP2K7 and neoplasm.